Trial Profile
Assessing sick leave (short-term absence), disability pension (long-term absence) and unemployment after switch from first-line disease-modifying drugs (interferon beta or glatirameracetat) to fingolimod
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 29 Oct 2018
Price :
$35
*
At a glance
- Drugs Fingolimod (Primary)
- Indications Multiple sclerosis
- Focus Therapeutic Use
- 29 Oct 2018 New trial record
- 12 Oct 2018 Results presented at the 34th Congress of the European Committee for Treatment and Research in Multiple Sclerosis